The U.S. Food and Drug Administration (FDA) has authorized the marketing of Essilor Stellest eyeglass lenses, the first glasses designed to both correct nearsightedness (myopia) and slow its progression in children ages 6 to 12.

This marks an important step in addressing the growing prevalence of childhood myopia, a condition which affects around 40% of the U.S population and is expected to affect more than 50% of the world population by 2050. If left untreated, it can impose serious vision threatening complications like glaucoma, cataracts, retinal detachment, and macular disease.

Unlike contact lenses—the only previously approved option for slowing myopia progression—the Essilor Stellest eyeglass lenses offer a lower-risk, easier-to-use alternative. They are especially beneficial for younger children or those unable to wear contacts.

The lenses feature a central clear zone surrounded by tiny peripheral lenslets that generate a special light focus pattern, helping to slow eye growth and, in turn, myopia progression. Clinical data from a two-year study showed impressive results: a 71% reduction in prescription worsening and a 53% reduction in eye elongation compared to standard lenses. No serious safety issues were reported, though some children experienced mild visual effects such as halos or blur.

The FDA studied the lenses under the De Novo premarket review pathway and granted them Breakthrough Device designation, recognizing their potential to significantly improve long-term eye health outcomes for children.

Essilor of America Inc. will now bring this innovative technology to market, offering parents and eye care providers a new tool to protect children’s vision and reduce future risks of severe eye disease.

Learn more: FdaFDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia